SCHEMBL19950862

SCHEMBL19950862

CNC(=O)c1ccc2ncc(Br)n2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.44
CLK1 P49759 1/20 0.44
RIPK2 O43353 2/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
PLK1 P53350 1/20 0.41
BAZ2B Q9UIF8 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
TGFBR1 P36897 4/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.38
FYN P06241 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27399110 0.85 KDM4E (0.48) KDM4EHPGDALDH1A1SCN10ASMN1; SMN2
SCHEMBL27399413 0.83 RIPK2 (0.39) RIPK2KDM4EHPGDALDH1A1SCN10A
SCHEMBL3033347 0.82 MAPK1 (0.45) RIPK2KDM4EALDH1A1TGFBR1
SCHEMBL19950854 0.81 KDM4E (0.49) RIPK2KDM4EHPGDALDH1A1SCN10A
SCHEMBL27399286 0.80 KDM4E (0.35) CLK1RIPK2KDM4EHPGDALDH1A1
SCHEMBL29229590 0.80 KDM4E (0.36) KDM4EHPGDALDH1A1SCN10ATGFBR1
SCHEMBL27399244 0.80 IRAK4 (0.42) KDM4ESCN10ATGFBR1FYNSMN1; SMN2
SCHEMBL19950919 0.79 IRAK4 (0.45) RIPK2KDM4EHPGDALDH1A1TGFBR1
SCHEMBL25148907 0.78 P4HTM (0.50) KDM4EHPGDALDH1A1SCN10AHTT
SCHEMBL25149588 0.78 KDM4E (0.54) KDM4EHPGDALDH1A1SCN10ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042901-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2025-02-06 US disclosed
US-12139484-B2 Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-11-12 US disclosed
CN-110023290-B Heteroaryl carboxamide compounds as RIPK2 inhibitors 勃林格殷格翰国际有限公司 2022-08-12 CN disclosed
US-20220081437-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2022-03-17 US disclosed
US-11130754-B2 Substituted benzamides as RIPK2 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-28 US disclosed
EP-3512833-B1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2020-07-29 EP disclosed
EP-3512833-B1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2020-07-29 EP disclosed
EP-3512833-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 Boehringer Ingelheim International GmbH (DE) 2019-07-24 EP disclosed
US-20190048000-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2019-02-14 US disclosed
US-10138241-B2 Substituted benzamides as RIPK2 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-11-27 US disclosed
WO-2018052772-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-03-22 WO disclosed
WO-2018052772-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-03-22 WO disclosed
US-20180072717-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190048000-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 RIPK2, RIPK1, RIPK4 ATM 3763/4885CLK1 928/4885RIPK2 1/4885
US-20180072717-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 RIPK2, RIPK1, RIPK3 ATM 3518/4885CLK1 936/4885RIPK2 1/4885
US-10138241-B2 Substituted benzamides as RIPK2 inhibitors RIPK2, RIPK4, RIPK1 ATM 2884/4885CLK1 1153/4885RIPK2 1/4885
US-20220081437-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 RIPK2, RIPK1, RIPK3 ATM 3518/4885CLK1 936/4885RIPK2 1/4885
US-11130754-B2 Substituted benzamides as RIPK2 inhibitors RIPK2, RIPK4, RIPK1 ATM 2884/4885CLK1 1153/4885RIPK2 1/4885
US-20250042901-A1 HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 RIPK2, RIPK1, RIPK4 ATM 3763/4885CLK1 928/4885RIPK2 1/4885
US-12139484-B2 Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease RIPK2, RIPK4, RIPK1 ATM 4096/4885CLK1 1249/4885RIPK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.